Gilead Sciences (NASDAQ:GILD) has made remdesivir, its Ebola-turned-COVID-19 drug, available to more than 1,700 patients through compassionate-use and expanded-access programs, according to an update from Gilead's chairman and CEO, Daniel O'Day, that was posted on the company's website on Saturday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,